miCAR Platform Enables Simultaneous Silencing of Multiple Gene Targets Allogene to Deploy miCAR and other Technologies to Create the Next Generation of Allogeneic Cell Products Antion is an ...
ALLO-715 will be Evaluated in Combination with ALLO-647, Allogene’s Proprietary anti-CD52 Antibody as Part of the Lymphodepletion Regimen Allogene Plans to Initiate the UNIVERSAL Study for ALLO-715 in ...
SOUTH SAN FRANCISCO, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T ...
Company Developed TurboCAR™ Technology Allows Cytokine Activation Signaling to be Engineered Selectively into CAR T Cells Preclinical Studies Provide Evidence That Cytokine Signaling Can Increase ...
Allogene Therapeutics presents an attractive investment opportunity in the biotechnology sector due to its focus on developing allogeneic CAR T products for cancer treatment. The recent announcement ...
Notch co-founder Juan Carlos Zúñiga-Pflücker, PhD. Allogene Therapeutics will partner with Notch Therapeutics to research and develop induced pluripotent stem cell (iPSC) AlloCAR™ therapies for ...
Allogene Therapeutics, Inc. (NASDAQ:ALLO) on Friday said it has selected standard fludarabine and cyclophosphamide (FC) as the lymphodepletion regimen to be used in its ALPHA3 study evaluating ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback